MedTrace Logo

Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders

NCT03147599 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-06-30

No results posted yet for this study

Summary

A randomized controlled trial to assess clinically the efficacy of the selective ileum spasmolytic mebeverine on daytime incontinence and nocturnal enuresis of orthotopic w-ileal neobladders and quality of life effect within 1 year post-surgery.

Conditions

  • Oncology
  • Incontinence
  • Incontinence, Daytime Urinary
  • Incontinence, Nighttime Urinary
  • Bladder Cancer
  • Orthotopic Neobladder

Interventions

DRUG

Coloverin

Mebeverine hydrochloride 135 mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Hassan Abol-Enein, MD · Urology and Nephrology Center

  • Ahmed Mosbah, MD · Urology and Nephrology Center

  • Ahmed Elhussein, MBBCH · Urology and Nephrology Center

  • Ahmed Elkarta, MBBCH · Urology and Nephrology Center

  • Mohamed Soltan, MBBCH · Urology and Nephrology Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03147599 on ClinicalTrials.gov